Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

866 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.
Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Holló P, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J. Ruzicka T, et al. Br J Dermatol. 2008 Apr;158(4):808-17. doi: 10.1111/j.1365-2133.2008.08487.x. Epub 2008 Feb 21. Br J Dermatol. 2008. PMID: 18294310 Clinical Trial.
Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial.
Ruzicka T, Larsen FG, Galewicz D, Horváth A, Coenraads PJ, Thestrup-Pedersen K, Ortonne JP, Zouboulis CC, Harsch M, Brown TC, Zultak M. Ruzicka T, et al. Arch Dermatol. 2004 Dec;140(12):1453-9. doi: 10.1001/archderm.140.12.1453. Arch Dermatol. 2004. PMID: 15611422 Clinical Trial.
Treatment of Darier disease with oral alitretinoin.
Letulé V, Herzinger T, Ruzicka T, Molin S. Letulé V, et al. Among authors: ruzicka t. Clin Exp Dermatol. 2013 Jul;38(5):523-5. doi: 10.1111/ced.12078. Clin Exp Dermatol. 2013. PMID: 23777494
A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.
Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, Brenninkmeijer EE, Smith C, Berth-Jones J, Ruzicka T, Sharpe G, Taieb A; 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. Reitamo S, et al. Among authors: ruzicka t. Br J Dermatol. 2008 Sep;159(4):942-51. doi: 10.1111/j.1365-2133.2008.08747.x. Epub 2008 Jul 15. Br J Dermatol. 2008. PMID: 18637898
Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.
Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T; European Tacrolimus Ointment Study Group. Thaçi D, et al. Among authors: ruzicka t. Br J Dermatol. 2008 Dec;159(6):1348-56. doi: 10.1111/j.1365-2133.2008.08813.x. Epub 2008 Sep 6. Br J Dermatol. 2008. PMID: 18782319 Clinical Trial.
Cyclosporine therapy in dermatology.
Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T. Mrowietz U, et al. Among authors: ruzicka t. J Dtsch Dermatol Ges. 2009 May;7(5):474-9. doi: 10.1111/j.1610-0387.2009.07077.x. Epub 2009 Mar 19. J Dtsch Dermatol Ges. 2009. PMID: 19302564 Review. English, German. No abstract available.
866 results